Developer docs
API playgroundTry for free, no card

Search company profiles

DFE Pharma

Full company profile

uuid000aes6

Namestring
DFE Pharma
Legal namestring
DFE Pharma GmbH & Co. KG
Websiteurl
dfepharma.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

DFE Pharma GmbH & Co. KG is a German-headquartered, privately held supplier of pharmaceutical and nutraceutical excipients, organized as a limited partnership under German law with wholly-owned operating subsidiaries in Germany (HQ in Goch), the United States, India, Japan, and China. The company develops, produces, and supplies functional excipients — primarily lactose variants (milled, spray-dried, granulated, anhydrous, micronized), cellulose-based ingredients (microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate), co-processed multifunctional excipients, and high-purity sugars (BioHale Sucrose and Trehalose Dihydrate) — that serve as fillers, binders, disintegrants, and stabilizers in oral solid dose, inhalation, biopharmaceutical, and nutraceutical formulations. The BioHale portfolio specifically targets biologics stabilization, with documented use in COVID-19 vaccines, and conforms to ICH Q7 guidelines alongside the European, US, Japanese, and Chinese Pharmacopoeias. Manufacturing is supported by FDA-inspected facilities and a brand heritage described as exceeding 100 years.

The company operates a direct B2B sales model combining field sales representatives, an inside sales team accessible through 'Request a Quote' and 'Request a Sample' website forms, and an 'Ask an Expert' technical consultation channel. Customer segments span Biopharmaceutical Companies, Inhalation Drug Developers (DPI), Oral Solid Dose Manufacturers, and Nutraceutical Companies, with pricing conducted on a quote basis rather than published rates. DFE Pharma self-identifies as a 'global leader' in pharma- and nutraceutical excipient solutions. In February 2026, the company launched a Continuous Manufacturing Platform in collaboration with Gericke, hosted at its C2F Center of Excellence in Hyderabad, India, extending its offering from excipient supply into formulation development and process optimization services aligned with ICH Q13 guidelines. CVC Capital Partners participated in a 2019 funding round, indicating institutional investor backing for ongoing expansion.

Short descriptiontext

DFE Pharma is a German-headquartered, global supplier of pharmaceutical and nutraceutical excipients — including lactose, microcrystalline cellulose, and high-purity sugars — serving biopharmaceutical, inhalation, oral solid dose, and nutraceutical manufacturers across Europe, the Americas, and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersGoch, Germany
HQ citystring
Goch
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical excipients, lactose excipient supply, biopharmaceutical stabilizers, dry powder inhaler lactose, oral solid dose excipients
Industry1 code
PRIMARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Excipients
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Excipient Sales
TypeOne Time License
Description

DFE Pharma generates revenue through the development, production, and supply of high-quality functional excipients for pharmaceutical and nutraceutical applications. The company sells directly to pharmaceutical manufacturers via a B2B model using direct sales teams, inside sales, and website-based quote/sample request processes. Products span multiple dosage forms including oral solid dose, inhalation, biopharma, and nutraceuticals.

dfepharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1BioHale
Description

High-purity excipients portfolio for biological products including BioHale Sucrose and BioHale Trehalose Dihydrate, used in biologics formulations and COVID-19 vaccines

dfepharma.com
+1 more record
Core offering1 text field

DFE Pharma develops, produces, and supplies functional pharmaceutical and nutraceutical excipients, including lactose variants, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, and high-purity BioHale sugars (sucrose, trehalose dihydrate). Products serve as fillers, binders, disintegrants, and stabilizers in oral solid dose, inhalation, biopharmaceutical, and nutraceutical formulations, sold directly to drug manufacturers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

DFE Pharma is a global leader in pharmaceutical and nutraceutical excipient solutions, operating as a single unified product portfolio rather than a modular platform. The core offering centers on functional excipients—primarily lactose variants (including spray-dried, anhydrous, and granulated forms) and cellulose-based ingredients (microcrystalline cellulose, croscarmellose sodium, and sodium starch glycolate)—used as fillers, binders, disintegrants, and stabilizers across oral solid dosage, inhalation, and biopharmaceutical applications. The BioHale® sub-brand (comprising Sucrose and Trehalose Dihydrate) provides high-purity, low-endotoxin excipients specifically for biological drug formulations including vaccines. A 2026 Continuous Manufacturing Platform, developed in partnership with Gericke and hosted at the C2F Center of Excellence in Hyderabad, extends the portfolio into process optimization services for pharmaceutical manufacturers transitioning to continuous production methods.

Product and service6 records
1Lactose Excipient Portfolio
CategoryPharmaceutical Excipients
Description

Comprehensive range of lactose variants used as fillers, binders, disintegrants, and stabilizers in oral solid dosage pharmaceutical and nutraceutical formulations.

2Cellulose and Starch Excipient Portfolio
CategoryPharmaceutical Excipients
Description

Comprehensive portfolio of cellulose products including microcrystalline cellulose (MCC), croscarmellose sodium, sodium starch glycolate, starches, and co-processed multifunctional excipients for pharmaceutical tablet and capsule formulations.

3BioHale Sucrose
CategoryBiopharmaceutical Excipients
Description

High-purity, low endotoxin sucrose excipient for stabilization of biological formulations in biopharmaceutical applications including parenteral, inhalation, oral, and ophthalmic administration routes. Conforms to F. Eur., USP-NF, JP, and ChP pharmacopeias.

4BioHale Trehalose Dihydrate
CategoryBiopharmaceutical Excipients
Description

High-purity, low endotoxin trehalose dihydrate excipient for stabilization of biological formulations in biopharmaceutical applications, conforming to F. Eur., USP-NF, JP, and ChP pharmacopeias.

5Inhalation Lactose (DPI Products)
CategoryInhalation Excipients
Description

Lactose-based excipients optimized for dry powder inhalation (DPI) therapies, including Lactohale 300 and DPI blend products, designed as vehicles to ensure controlled release of active pharmaceutical ingredients to the lungs with customizable properties matched to specific device and molecule combinations.

6Continuous Manufacturing Platform
CategoryManufacturing Process Platform
Description

Collaborative platform with Gericke enabling pharmaceutical companies to test formulation strategies and evaluate continuous manufacturing processes, featuring CM-ready excipients, a testing environment at the C2F Center of Excellence in Hyderabad, India, and regulatory alignment with ICH Q13 guidelines.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

DFE Pharma launched a Continuous Manufacturing platform in collaboration with Gericke to support pharmaceutical companies in formulation development, process optimization, and lifecycle management of continuous manufacturing (CM) operations. The platform combines CM-ready excipients, a testing environment at DFE Pharma's C2F Center of Excellence in Hyderabad, India (featuring a Gericke Formulation Skid with modular dosing and mixing options in a non-GMP environment), and multidisciplinary expertise from both companies to enable data-driven decisions from early exploration through long-term operations, aligned with ICH Q13 regulatory guidelines.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Roquette is a global leader in starch, polyols, and pharmaceutical excipients, including lactose, microcrystalline cellulose, and specialty binders—directly competing with DFE Pharma across OSD, biopharma, and nutraceutical dosage forms.

TypeBroad incumbent
Description

BASF's pharma solutions division supplies excipients, APIs, and intermediates globally, overlapping with DFE Pharma on functional excipients while offering a much wider chemistry and ingredient portfolio.

TypeDirect peer
Description

Meggle is a Germany-headquartered specialist in lactose-based pharmaceutical excipients for OSD and inhalation, overlapping directly with DFE Pharma's core lactose and Lactohale portfolios.

TypeDirect peer
Description

JRS Pharma manufactures cellulose-based excipients (MCC, croscarmellose sodium) and binders/starches for OSD formulations, directly competing with DFE Pharma's cellulose and starch portfolio.

TypeDirect peer
Description

Ashland produces pharmaceutical excipients including coatings, binders, disintegrants, and specialty polymers for OSD and biopharma applications, directly competing with DFE's excipient portfolio.

TypeEmerging player
Description

Ingredion supplies specialty starches and ingredient systems with growing pharma/nutraceutical applications, providing partial overlap with DFE's starch and cellulose-based excipient lines.

TypeBroad incumbent
Description

Evonik's specialty additives and pharma polymer businesses produce excipient and delivery ingredients serving OSD and parenteral applications, competing as a broader specialty chemicals incumbent.

8Shin-Etsu Chemical
TypeRegional player
Description

Shin-Etsu supplies pharmaceutical excipients including MCC and coating polymers, primarily serving Japanese and Asian markets—an overlapping product portfolio with DFE but with regional concentration.

TypeBroad incumbent
Description

Kerry's pharma and nutrition ingredients business offers excipients and functional ingredients for pharma and nutraceutical manufacturers, overlapping with DFE's nutraceutical and OSD portfolios as a broader ingredient platform.

10DuPont (now IFF Health & Biosciences)
TypeBroad incumbent
Description

DuPont's Nutrition & Biosciences (now part of IFF) supplies pharmaceutical excipients including MCC and specialty ingredients, serving as a broader incumbent competing with DFE across multiple dosage forms.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DFE Pharma

Pharmaceutical Excipientsdfepharma.com

DFE Pharma is a German-headquartered, global supplier of pharmaceutical and nutraceutical excipients — including lactose, microcrystalline cellulose, and high-purity sugars — serving biopharmaceutical, inhalation, oral solid dose, and nutraceutical manufacturers across Europe, the Americas, and Asia.

What DFE Pharma does

DFE Pharma GmbH & Co. KG is a German-headquartered, privately held supplier of pharmaceutical and nutraceutical excipients, organized as a limited partnership under German law with wholly-owned operating subsidiaries in Germany (HQ in Goch), the United States, India, Japan, and China. The company develops, produces, and supplies functional excipients — primarily lactose variants (milled, spray-dried, granulated, anhydrous, micronized), cellulose-based ingredients (microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate), co-processed multifunctional excipients, and high-purity sugars (BioHale Sucrose and Trehalose Dihydrate) — that serve as fillers, binders, disintegrants, and stabilizers in oral solid dose, inhalation, biopharmaceutical, and nutraceutical formulations. The BioHale portfolio specifically targets biologics stabilization, with documented use in COVID-19 vaccines, and conforms to ICH Q7 guidelines alongside the European, US, Japanese, and Chinese Pharmacopoeias. Manufacturing is supported by FDA-inspected facilities and a brand heritage described as exceeding 100 years.

The company operates a direct B2B sales model combining field sales representatives, an inside sales team accessible through 'Request a Quote' and 'Request a Sample' website forms, and an 'Ask an Expert' technical consultation channel. Customer segments span Biopharmaceutical Companies, Inhalation Drug Developers (DPI), Oral Solid Dose Manufacturers, and Nutraceutical Companies, with pricing conducted on a quote basis rather than published rates. DFE Pharma self-identifies as a 'global leader' in pharma- and nutraceutical excipient solutions. In February 2026, the company launched a Continuous Manufacturing Platform in collaboration with Gericke, hosted at its C2F Center of Excellence in Hyderabad, India, extending its offering from excipient supply into formulation development and process optimization services aligned with ICH Q13 guidelines. CVC Capital Partners participated in a 2019 funding round, indicating institutional investor backing for ongoing expansion.

DFE Pharma firmographics

Firmographics
Name
DFE Pharma
Legal name
DFE Pharma GmbH & Co. KG
Website
https://dfepharma.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
501–1,000 employees
Short description
DFE Pharma is a German-headquartered, global supplier of pharmaceutical and nutraceutical excipients — including lactose, microcrystalline cellulose, and high-purity sugars — serving biopharmaceutical, inhalation, oral solid dose, and nutraceutical manufacturers across Europe, the Americas, and Asia.
Ownership category
akta.pro rank

DFE Pharma industry classification

Industry
Product category
Pharmaceutical Excipients
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)

Keywords

  • Pharmaceutical excipients
  • Lactose excipient supply
  • Biopharmaceutical stabilizers
  • Dry powder inhaler lactose
  • Oral solid dose excipients

Where DFE Pharma is headquartered

Location

Headquarters

HQ city
Goch
HQ country
Germany
HQ region
Europe

Offices5 records

Markets served

DFE Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Excipient Sales: DFE Pharma generates revenue through the development, production, and supply of high-quality functional excipients for pharmaceutical and nutraceutical applications. The company sells directly to pharmaceutical manufacturers via a B2B model using direct sales teams, inside sales, and website-based quote/sample request processes. Products span multiple dosage forms including oral solid dose, inhalation, biopharma, and nutraceuticals.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

DFE Pharma product offering

Product offering

Core offering

DFE Pharma develops, produces, and supplies functional pharmaceutical and nutraceutical excipients, including lactose variants, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, and high-purity BioHale sugars (sucrose, trehalose dihydrate). Products serve as fillers, binders, disintegrants, and stabilizers in oral solid dose, inhalation, biopharmaceutical, and nutraceutical formulations, sold directly to drug manufacturers.

Product overview

DFE Pharma is a global leader in pharmaceutical and nutraceutical excipient solutions, operating as a single unified product portfolio rather than a modular platform. The core offering centers on functional excipients—primarily lactose variants (including spray-dried, anhydrous, and granulated forms) and cellulose-based ingredients (microcrystalline cellulose, croscarmellose sodium, and sodium starch glycolate)—used as fillers, binders, disintegrants, and stabilizers across oral solid dosage, inhalation, and biopharmaceutical applications. The BioHale® sub-brand (comprising Sucrose and Trehalose Dihydrate) provides high-purity, low-endotoxin excipients specifically for biological drug formulations including vaccines. A 2026 Continuous Manufacturing Platform, developed in partnership with Gericke and hosted at the C2F Center of Excellence in Hyderabad, extends the portfolio into process optimization services for pharmaceutical manufacturers transitioning to continuous production methods.

Differentiator

Problem solved

Functional benefit

Brands

  • BioHale: High-purity excipients portfolio for biological products including BioHale Sucrose and BioHale Trehalose Dihydrate, used in biologics formulations and COVID-19 vaccines
  • Lactohale

Products and services

  • Lactose Excipient Portfolio Comprehensive range of lactose variants used as fillers, binders, disintegrants, and stabilizers in oral solid dosage pharmaceutical and nutraceutical formulations.
  • Cellulose and Starch Excipient Portfolio Comprehensive portfolio of cellulose products including microcrystalline cellulose (MCC), croscarmellose sodium, sodium starch glycolate, starches, and co-processed multifunctional excipients for pharmaceutical tablet and capsule formulations.
  • BioHale Sucrose High-purity, low endotoxin sucrose excipient for stabilization of biological formulations in biopharmaceutical applications including parenteral, inhalation, oral, and ophthalmic administration routes. Conforms to F. Eur., USP-NF, JP, and ChP pharmacopeias.
  • BioHale Trehalose Dihydrate High-purity, low endotoxin trehalose dihydrate excipient for stabilization of biological formulations in biopharmaceutical applications, conforming to F. Eur., USP-NF, JP, and ChP pharmacopeias.
  • Inhalation Lactose (DPI Products) Lactose-based excipients optimized for dry powder inhalation (DPI) therapies, including Lactohale 300 and DPI blend products, designed as vehicles to ensure controlled release of active pharmaceutical ingredients to the lungs with customizable properties matched to specific device and molecule combinations.
  • Continuous Manufacturing Platform Collaborative platform with Gericke enabling pharmaceutical companies to test formulation strategies and evaluate continuous manufacturing processes, featuring CM-ready excipients, a testing environment at the C2F Center of Excellence in Hyderabad, India, and regulatory alignment with ICH Q13 guidelines.

Companies that use DFE Pharma

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

DFE Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

DFE Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • GerickecoreStrategic or Co-development Partner · 18 February 2026DFE Pharma launched a Continuous Manufacturing platform in collaboration with Gericke to support pharmaceutical companies in formulation development, process optimization, and lifecycle management of continuous manufacturing (CM) operations. The platform combines CM-ready excipients, a testing environment at DFE Pharma's C2F Center of Excellence in Hyderabad, India (featuring a Gericke Formulation Skid with modular dosing and mixing options in a non-GMP environment), and multidisciplinary expertise from both companies to enable data-driven decisions from early exploration through long-term operations, aligned with ICH Q13 regulatory guidelines.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

DFE Pharma competitors and assessment

Company assessment

Direct peers

  • Roquette: Roquette is a global leader in starch, polyols, and pharmaceutical excipients, including lactose, microcrystalline cellulose, and specialty binders—directly competing with DFE Pharma across OSD, biopharma, and nutraceutical dosage forms.
  • Meggle: Meggle is a Germany-headquartered specialist in lactose-based pharmaceutical excipients for OSD and inhalation, overlapping directly with DFE Pharma's core lactose and Lactohale portfolios.
  • JRS Pharma: JRS Pharma manufactures cellulose-based excipients (MCC, croscarmellose sodium) and binders/starches for OSD formulations, directly competing with DFE Pharma's cellulose and starch portfolio.
  • Ashland: Ashland produces pharmaceutical excipients including coatings, binders, disintegrants, and specialty polymers for OSD and biopharma applications, directly competing with DFE's excipient portfolio.

Broad incumbents

  • BASF: BASF's pharma solutions division supplies excipients, APIs, and intermediates globally, overlapping with DFE Pharma on functional excipients while offering a much wider chemistry and ingredient portfolio.
  • Evonik: Evonik's specialty additives and pharma polymer businesses produce excipient and delivery ingredients serving OSD and parenteral applications, competing as a broader specialty chemicals incumbent.
  • Kerry Group: Kerry's pharma and nutrition ingredients business offers excipients and functional ingredients for pharma and nutraceutical manufacturers, overlapping with DFE's nutraceutical and OSD portfolios as a broader ingredient platform.
  • DuPont (now IFF Health & Biosciences): DuPont's Nutrition & Biosciences (now part of IFF) supplies pharmaceutical excipients including MCC and specialty ingredients, serving as a broader incumbent competing with DFE across multiple dosage forms.

Emerging players

  • Ingredion: Ingredion supplies specialty starches and ingredient systems with growing pharma/nutraceutical applications, providing partial overlap with DFE's starch and cellulose-based excipient lines.

Regional players

  • Shin-Etsu Chemical: Shin-Etsu supplies pharmaceutical excipients including MCC and coating polymers, primarily serving Japanese and Asian markets—an overlapping product portfolio with DFE but with regional concentration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

DFE Pharma social profiles

Digital presence

DFE Pharma compliance and trust

Trust signal

Compliance5 records

DFE Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DFE Pharma leadership team

Management profile

Number of profiles

Profiles1 record

DFE Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

DFE Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DFE Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DFE Pharma

What does DFE Pharma do?

DFE Pharma develops, produces, and supplies functional pharmaceutical and nutraceutical excipients, including lactose variants, microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, and high-purity BioHale sugars (sucrose, trehalose dihydrate). Products serve as fillers, binders, disintegrants, and stabilizers in oral solid dose, inhalation, biopharmaceutical, and nutraceutical formulations, sold directly to drug manufacturers.

Is DFE Pharma a public or private company?

DFE Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was DFE Pharma founded?

DFE Pharma was founded in 2005. It employs 501 to 1,000 people.

Where is DFE Pharma based?

DFE Pharma is headquartered in Goch, Germany, in the Europe region.

How does DFE Pharma make money?

One revenue line is on record: pharmaceutical Excipient Sales.

Who are DFE Pharma's main competitors?

Direct peers on record are Roquette, Meggle, JRS Pharma and Ashland. Broad incumbents are BASF, Evonik, Kerry Group and DuPont (now IFF Health & Biosciences). Ingredion is listed as an emerging player. Shin-Etsu Chemical is listed as a regional player.

Does DFE Pharma have an API?

No public API is recorded for DFE Pharma.

What industry is DFE Pharma in?

DFE Pharma's product category is Pharmaceutical Excipients. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TalkMarketsPharmaceutical Pregelatinized Starch Market to Reach USD 2.70 Billion by 2034, Driven by Expanding Pharmaceutical Manufacturing and Generic Drug ProductionThe global pharmaceutical pregelatinized starch market, valued at USD 1.86 billion in 2025, is projected to grow at a CAGR of 4.2% to reach USD 2.70 billion by 2034, driven by expanding pharmaceutical manufacturing, rising generic drug production, and increasing demand for solid oral dosage forms. The market's growth is underpinned by the versatility of pregelatinized starch as a multifunctional excipient serving as binder, disintegrant, and filler, alongside favorable regulatory support from agencies like the FDA and EMA. Key market players including Roquette, Cargill, Colorcon, DFE Pharma, and Beneo are positioned to benefit from growth in emerging economies such as India and China, which account for over 40% of global generic drug production.Precedence ResearchUS Pharmaceutical Excipients Market Size to Hit USD 5.58 Billion by 2035The US pharmaceutical excipients market is projected to grow from USD 3.08 billion in 2025 to USD 5.58 billion by 2035, expanding at a compound annual growth rate of 6.12%. This expansion is primarily driven by increasing demand for biologics, specialty drugs, and advanced formulations requiring high-performance ingredients, alongside the integration of artificial intelligence in drug development. Key industry players such as DFE Pharma, MEGGLE Pharma, Roquette, and Evonik are actively investing in capacity expansion and technological innovation to meet these rising requirements.Express PharmaDFE Pharma launches Continuous Manufacturing platform in collaboration with GerickeDFE Pharma has launched a Continuous Manufacturing platform in collaboration with Gericke to support pharmaceutical companies in formulation development, process optimization and lifecycle management of CM operations. The platform combines CM-ready excipients, a testing environment at DFE Pharma's C2F Center of Excellence in Hyderabad, India, and multidisciplinary expertise from both companies to enable data-driven decisions from early exploration through long-term operations. The collaboration is designed to assist pharmaceutical companies in implementing development and registration strategies aligned with regulatory principles including ICH Q13.StartseiteDFE Pharma Launches Continuous Manufacturing Platform for Formulation DevelopmentDFE Pharma, in collaboration with Gericke, has launched a continuous manufacturing platform for pharmaceutical formulation development, investing in a continuous manufacturing capability at the C2F Center of Excellence in Hyderabad, India. The platform features a Gericke Formulation Skid with modular dosing and mixing options located in a non-GMP environment, enabling pharmaceutical companies to test formulation strategies and evaluate continuous manufacturing processes without disrupting existing operations. This initiative aims to help pharmaceutical companies accelerate learning, reduce uncertainty, and implement robust development and registration strategies in line with ICH Q13 regulatory guidelines.BioSpectrum IndiaDFE Pharma launches Continuous Manufacturing platform to accelerate formulation development in HyderabadDFE Pharma has launched a Continuous Manufacturing (CM) platform in collaboration with Gericke to accelerate formulation development for pharmaceutical companies. The initiative centers on the C2F Center of Excellence in Hyderabad, which features a Gericke Formulation Skid designed to enable fast iterations and practical assessment of CM processes.ContractpharmaDFE Pharma Launches Continuous Manufacturing Platform with GerickeDFE Pharma, a global leader in pharmaceutical excipients, has launched a Continuous Manufacturing platform in collaboration with Gericke to support pharmaceutical companies in formulation development, optimization, and lifecycle management of CM processes. As part of this initiative, DFE Pharma has invested in continuous manufacturing capability at its C2F Center of Excellence in Hyderabad, India, featuring a Gericke Formulation Skid that enables flexible process and formulations testing in a non-GMP environment. The platform combines CM-ready excipients, testing infrastructure, and multidisciplinary expertise to enable data-driven decisions from early exploration through long-term operation.openPR.comCellulose Gel Market Dynamics and Future Growth Overview 2024 - 2031 | Sigachi Industrial Pvt. Ltd., DFE Pharma GmbH & Co. KGThe cellulose gel market is expected to grow significantly over 2024-2031, driven by pharmaceutical demand, cosmetics use, and food applications. The pharmaceutical industry is growing at 4-7% annually, and cellulose gel is used as a thickening agent and textile sizing agent. Innovation in clean label and specialty cellulose gel is a key trend.BusinessLineDFE Pharma opens Centre of Excellence in HyderabadDFE Pharma opened its Closer to the Formulator (C2F) Center of Excellence in Hyderabad's Genome Valley, a 1,200 sq m laboratory. The center aims to shorten time from concept to commercial product and reduce formulation spending. Executives said it will help customers develop new ideas and address challenges.outsourcing-pharma.com3D tablet printing needs the right excipient: DFE PharmaDFE Pharma's senior product developer discussed 3D powder bed printing of tablets, highlighting lactose as a suitable excipient after testing 20 grades. The research found lactose blends with d10 >10μm and 10% pregelatinized starch produced tablets with acceptable hardness and friability. The company plans to build a centralized dataset to accelerate industry progress.